Knoll Synthroid
Executive Summary
Marketing litigation settlement establishes $87 mil. consumer class fund to provide "approximately 778,000 consumer settlement class members with...at least $84 for each claimant who bought Synthroid before 1995 and $55 for those who bought it starting in 1995," Chicago federal court Judge Elaine Bucklo ruled Aug. 4. The class action suits cited Knoll's delay of publication of a Dong et al. study that found certain branded and generic levothyroxine sodium products were bioequivalent to Knoll's thyroid medication. Under the settlement, about $46 mil. will also be paid to third-party payer class members